The health portfolio has previously been dubbed a 'poisoned chalice' — so what are the challenges facing the new ministers in health, mental health, and disability? Jennifer Carroll MacNeill ...

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ahead of AbbVie’s Rinvoq and Skyrizi three months into its ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting off on a very different note. According to iSpot.TV’s analysis of ...

Skyrizi and Rinvoq are expected to generate nearly $24 billion in combined sales in 2025, reflecting a $6 billion increase year-over-year. AbbVie raised its 2027 combined sales guidance for these ...

The National Union of Seamen, Ports, and Allied Workers (NUSPAW) of TUC Ghana, has extended its heartfelt congratulations to Ebow Mensah on his recent re-appointment as the Administrator of Premix ...

The decline was offset by sales of its newer arthritis drugs Skyrizi, which soared by 57% to $3.78 billion, and Rinvoq, which logged a 46% gain to $1.83 billion. Chief Executive Robert Michael ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD ...

Chalice Mining has appointed Dan Brearley as its chief operating officer from March 3. The newly created role aims to bolster Chalice’s senior leadership team as it advances the Gonneville ...

Objective The children's head injury algorithm for the prediction of important clinical events (CHALICE) is one of the strongest clinical prediction rules for the management of children with head ...

and insights straight to your inbox.